Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity ; volume:13 ; number:1 ; day:28 ; month:11 ; year:2023 ; pages:1-12 ; date:12.2023
Scientific reports ; 13, Heft 1 (28.11.2023), 1-12, 12.2023
- Creator
-
Quddos, Fatima
Hubshman, Zachary
Tegge, Allison
Sane, Daniel
Marti, Erin
Kablinger, Anita S.
Gatchalian, Kirstin M.
Kelly, Amber L.
DiFeliceantonio, Alexandra G.
Bickel, Warren K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-48267-2
- URN
-
urn:nbn:de:101:1-2024021511190633844310
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Quddos, Fatima
- Hubshman, Zachary
- Tegge, Allison
- Sane, Daniel
- Marti, Erin
- Kablinger, Anita S.
- Gatchalian, Kirstin M.
- Kelly, Amber L.
- DiFeliceantonio, Alexandra G.
- Bickel, Warren K.
- SpringerLink (Online service)
Other Objects (12)
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial